Detail for amiodarone
Basic Information
DrugID 6
DrugName amiodarone
DrugDetail Amiodarone is an antiarrhythmic agent (medication used for irregular heart beat) used for various types of tachyarrhythmias (fast forms of irregular heart beat), both ventricular and supraventricular (atrial) arrhythmias ( that is affecting the upper and lower chambers of the heart) . It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance.

http://www.drugbank.ca/drugs/DB01118

http://en.wikipedia.org/wiki/Amiodarone

Indication Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.

http://www.drugbank.ca/drugs/DB01118

http://www.rxlist.com/amiodarone-hcl-injection-drug/indications-dosage.htm

Structure Click to see the orginal picture.
Interaction
Drug Name PMIDLink Reference
Fluconazole Gamarra S, Rocha EM, Zhang YQ, Park S, Rao R, Perlin DS. (2010) Mechanism of the synergistic effect ofand fluconazole in Candida albicans. Antimicrob Agents Chemother. 54(5):1753-61.
Fluconazole Guo Q, Sun S, Li Y, Yu J, Shi C. (2008) In vitro interactions between azoles andagainst clinical Candida albicans. Int J Antimicrob Agents. 31(1):88-90.
Itraconazole Guo Q, Sun S, Li Y, Yu J, Shi C. (2008) In vitro interactions between azoles andagainst clinical Candida albicans. Int J Antimicrob Agents. 31(1):88-90.
Itraconazole Afeltra J, Vitale RG, Mouton JW, Verweij PE. (2004) Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob Agents Chemother. 48(4):1335-43.
Voriconazole Guo Q, Sun S, Li Y, Yu J, Shi C. (2008) In vitro interactions between azoles andagainst clinical Candida albicans. Int J Antimicrob Agents. 31(1):88-90.
Micafungin Nishi I., Sunada A., Toyokawa M., Asari S., Iwatani Y. (2009) In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species (vol 15, pg 1, 2009). Journal of Infection and Chemotherapy 15:123-124. DOI: 10.1007/s10156-009-0002-7
Target
TargetName References EssentialGene? Link
(R)-limonene 6-monooxygenase No
Albendazole monooxygenase No
Alpha-1A adrenergic receptor No
Anthrax lethal toxin endopeptidase component No
ATP-binding cassette sub-family B member 1 No
Beta-1 adrenergic receptor Yes
c-erbA-1 Yes
CYPIA1 No
CYPIA2 Yes
CYPIIC8 No
CYPIID6 No
CYPIIIA5 No
CYPIIIA7 No
Cytochrome P450 Yes
Cytochrome P450 3A4 No
Cytochrome P450 CYP3A4 No
Cytochrome P450 family 3 subfamily A polypeptide 4 No
Nuclear receptor subfamily 1 group A member 2 Yes
Potassium voltage-gated channel subfamily H member 2 No
Voltage-dependent T-type calcium channel subunit alpha-1H No
Voltage-dependent calcium channel subunit alpha-2/delta-2 Yes
voltage-gated potassium channel (KCND3) blocker No
voltage-gated potassium channel (KCNH2) blocker No
voltage-gated potassium channel (KCNQ1) blocker No
potassium inwardly-rectifying channel (KCNJ3) No
potassium inwardly-rectifying channel (KCNJ5) No
potassium inwardly-rectifying channel (KCNJ8) No
potassium inwardly-rectifying channel (KCNJ11) No
potassium inwardly-rectifying channel (KCNJ12) No
voltage-gated sodium channel blocker No
P-glycoprotein inhibitor No
alpha1-adrenergic receptor agonist No
beta1-adrenergic receptor agonist No
PathWay